We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Expands in Croatia with Edge Radiosurgery Product
Read MoreHide Full Article
Palo Alto, CA-based Varian Medical Systems, Inc. , a leading manufacturer of medical devices and software for treating cancer with radiation, recently announced that its flagship product Edge Radiosurgery system is being installed at Croatia-based Radiochirurgia Zagreb Clinic. Radiosurgical treatments using the system are expected to start by Jan 2017.
Meanwhile, over the last six months, the stock represents a solid return of almost 11.5%, comparing favorably with the Zacks categorized Medical Instruments sub-industry’s negative return of roughly 2.2%. However, Varian’s shares did not follow the favorable market trend, declining a nominal 0.6% to close at $91.06 following the news.
We are concerned about the unfavorable estimate revision trend for the stock as three estimates moved south in the last two months. Notably, the current year estimates for the stock dropped by 3 cents to $4.93 per share over the same time frame.
On a brighter note, one estimate moved north in the last one month. Additionally, a long-term expected earnings growth rate of 15% and an earnings yield of 5.4%, compared to the industry’s negative yield of 4.3% instill investor confidence on the stock.
Coming back to the latest development, the system marks Southeastern Europe's first Edge product from Varian. In this regard, the system delivers full-body radiosurgery treatment with precision.
Per management, the system will allow patients in the region to access a wide range of early-stage cancer screening procedures. The expansion in Croatia fortifies Varian’s foothold in Europe, a major participant in the global radiotherapy market. On this note, the global radiotherapy market is forecasted to reach a worth of $7,544.8 million by 2020, multiplying at a CAGR of 6.2% (Markets And Markets).
Our Take
Of late, Varian has been gaining prominence, courtesy of its solid oncology business prospects. We note that the company addresses both tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam products.
We are also upbeat about the company’s first-quarter fiscal 2017 guidance wherein revenues are expected to increase about 1% to 2% on a year-over-year basis.
Of the other developments, Varian was recently included in the inaugural JUST 100 List. Per the list, Varian is the nation’s ‘Most JUST Company’ in the Healthcare Equipment and Services industry. Notably, the list was prepared by independent non-profit organization JUST Capital and Forbes magazine.
On the flip side, the company promises a negative return of 0.6% in terms of projected sales for the current year, comparing unfavorably with the industry’s 6.3% sales growth.
Zacks Rank & Key Picks
Currently, Varian has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and HMS Holdings Corp. . Addus HomeCare and LHC Group sport a Zacks Rank #1 (Strong Buy) while HMS Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 47.9%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 2.4% in the last one month.
HMS Holdings has an expected earnings growth of almost 14.3%. The company posted a promising year-to-date return of 48%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Varian Expands in Croatia with Edge Radiosurgery Product
Palo Alto, CA-based Varian Medical Systems, Inc. , a leading manufacturer of medical devices and software for treating cancer with radiation, recently announced that its flagship product Edge Radiosurgery system is being installed at Croatia-based Radiochirurgia Zagreb Clinic. Radiosurgical treatments using the system are expected to start by Jan 2017.
Meanwhile, over the last six months, the stock represents a solid return of almost 11.5%, comparing favorably with the Zacks categorized Medical Instruments sub-industry’s negative return of roughly 2.2%. However, Varian’s shares did not follow the favorable market trend, declining a nominal 0.6% to close at $91.06 following the news.
We are concerned about the unfavorable estimate revision trend for the stock as three estimates moved south in the last two months. Notably, the current year estimates for the stock dropped by 3 cents to $4.93 per share over the same time frame.
On a brighter note, one estimate moved north in the last one month. Additionally, a long-term expected earnings growth rate of 15% and an earnings yield of 5.4%, compared to the industry’s negative yield of 4.3% instill investor confidence on the stock.
Coming back to the latest development, the system marks Southeastern Europe's first Edge product from Varian. In this regard, the system delivers full-body radiosurgery treatment with precision.
VARIAN MEDICAL Price
VARIAN MEDICAL Price | VARIAN MEDICAL Quote
Per management, the system will allow patients in the region to access a wide range of early-stage cancer screening procedures. The expansion in Croatia fortifies Varian’s foothold in Europe, a major participant in the global radiotherapy market. On this note, the global radiotherapy market is forecasted to reach a worth of $7,544.8 million by 2020, multiplying at a CAGR of 6.2% (Markets And Markets).
Our Take
Of late, Varian has been gaining prominence, courtesy of its solid oncology business prospects. We note that the company addresses both tier 1 and mid-tier markets through its Edge, Truebeam and VitalBeam products.
We are also upbeat about the company’s first-quarter fiscal 2017 guidance wherein revenues are expected to increase about 1% to 2% on a year-over-year basis.
Of the other developments, Varian was recently included in the inaugural JUST 100 List. Per the list, Varian is the nation’s ‘Most JUST Company’ in the Healthcare Equipment and Services industry. Notably, the list was prepared by independent non-profit organization JUST Capital and Forbes magazine.
On the flip side, the company promises a negative return of 0.6% in terms of projected sales for the current year, comparing unfavorably with the industry’s 6.3% sales growth.
Zacks Rank & Key Picks
Currently, Varian has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and HMS Holdings Corp. . Addus HomeCare and LHC Group sport a Zacks Rank #1 (Strong Buy) while HMS Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 47.9%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 2.4% in the last one month.
HMS Holdings has an expected earnings growth of almost 14.3%. The company posted a promising year-to-date return of 48%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>